TA269 Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: costing template
|
TA269 Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: costing template
12 December 2012 (511.5 Kb 2 mins 28 sec) |
This page was last updated: 09 January 2013